Third Rock Ventures
United States
42 articles about Third Rock Ventures
-
New Coalition Aims To Close The Opportunity Gap In Bioscience
12/3/2020
Bioscience & Investor Inclusion Group (BIIG) founding members include Liftstream, New England Venture Capital Association, Third Rock Ventures, Biogen and BioDirector
-
Third Rock Ventures Raises $770 Million Fund V
6/6/2019
Third Rock has raised $2.7 billion to create companies focused in many different areas of high unmet medical need including cancer, neurological disorders, rare genetic diseases, immune disorders, and cardiovascular diseases.
-
This is the largest fund in the 12 years Third Rock has been in existence. The company indicates it will use the money to seed 10 to 12 life science companies.
-
Maze Therapeutics Launches with $191 Million to Focus on Translating Genetic Insights into New Medicines
2/28/2019
Third Rock Ventures announced the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines.
-
Third Rock Ventures Names Christoph Lengauer, Ph.D., and Jeffrey Tong, Ph.D., as Partners
12/13/2018
Scientific and strategic leaders bring significant operating experience to the firm’s company creation mission
-
The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.
-
Six months after launching with $60 million, Cambridge, Mass.-based Rheos Medicines has tapped Roche veteran Sanjay Keswani as the startup's new chief executive officer.
-
Fulcrum Therapeutics Raises $80 Million Series B From Investors, Including Sanofi and Bill Maris'...
9/5/2018
Fulcrum Therapeutics, based in Cambridge, Massachusetts, closed on an $80 million Series B financing. -
Merus Announces Formation of a Scientific Advisory Board
8/22/2018
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
-
Ambys Medicines Launches with $140 Million to Pioneer Regenerative Medicine Therapies for Serious Liver Diseases
8/8/2018
Ambys also announced today a strategic partnership with Takeda bringing total committed funding at launch to $140 million.
-
Ambys Medicines, based in Redwood City, California, has launched in an unusual deal with Osaka, Japan’s Takeda Pharmaceutical Company.
-
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
-
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
-
Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-Mediated Diseases
3/22/2018
Rheos Medicines, Inc. was launched today with $60 million in Series A financing backed by Third Rock Ventures, LLC.
-
Third Rock Ventures Quietly Launches Tango Therapeutics in Editas Medicine’s HQ
3/8/2017
-
Third Rock Ventures Release: Company Names Sarah Larson As Partner
1/26/2017
-
Third Rock Ventures Names Industry Leader Michael W. Bonney As Partner
1/7/2016
-
Third Rock Ventures and GlaxoSmithKline’s SR One Launch Decibel Therapeutics With $52 Million, Expect to Hire 50-60 By Year End
10/16/2015
-
Third Rock Ventures Leads Formation of Neon Therapeutics with $55 Million Series A Round
10/2/2015
-
Ember Therapeutics and Third Rock Ventures — A Case Study in the Risks of Biotech Investments
9/11/2015